IHWM
TOVX icon

Iron Horse Wealth Management’s Theriva Biologics TOVX Stock Holding History

Iron Horse Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14
Closed -$25 – 641
2024
Q4 		$25 Hold
14
– – ﹤0.01% 503
2024
Q3 		$19 Sell
14
-1
-7% -$5 ﹤0.01% 504
2024
Q2 		$86 Hold
15
– – ﹤0.01% 473
2024
Q1 		$171 Buy
+15
New +$176 ﹤0.01% 450

Other funds holding TOVX

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return

Iron Horse Wealth Management's TOVX Position: Q1 2025 in Review

Iron Horse Wealth Management sold out of Theriva Biologics (TOVX) in Q1 2025, closing a stake of 14 shares — an estimated $25 sold.

Iron Horse Wealth Management first reported a position in TOVX in Q1 2024 and held it in 4 quarters. The position peaked at $171 in Q1 2024. 11 funds tracked by Wall St. Rank hold TOVX as of Q1 2025.

  • Iron Horse Wealth Management reported no remaining Theriva Biologics position as of Q1 2025 after selling out during the quarter.
  • Iron Horse Wealth Management sold 14 Theriva Biologics shares in Q1 2025, an estimated $25.
  • Iron Horse Wealth Management first reported a position in Theriva Biologics in Q1 2024 and held it in 4 quarters.
  • Iron Horse Wealth Management's Theriva Biologics position peaked at $171 in Q1 2024.
  • 11 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2025.

Based on Iron Horse Wealth Management's 13F filing for Q1 2025, filed 1 May 2025.